OncoMatch/Clinical Trials/NCT06880523

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

Is NCT06880523 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including STRIDE (durvalumab + tremelimumab) and Durvalumab for hepatocellular carcinoma.

Phase 2RecruitingCanadian Cancer Trials GroupNCT06880523Data as of May 2026

Treatment: STRIDE (durvalumab + tremelimumab) · Durvalumab · Lenvatinib — The purpose of this study is to compare the effects on participants' and liver cancer by adding a drug that is used on its own to treat this disease to a combination of two other drugs which is also used to treat liver cancer, compared to the two-drug combination alone.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Disease stage

Required: Stage BCLC STAGE B (NOT ELIGIBLE FOR LOCOREGIONAL THERAPY), BCLC STAGE C (BCLC)

Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: PD-1 inhibitor (durvalumab)

Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab

Cannot have received: PD-L1 inhibitor (durvalumab)

Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab

Cannot have received: anti-CTLA-4 therapy (tremelimumab)

Any previous treatment with ... anti-CTLA4, including tremelimumab

Lab requirements

Liver function

child-pugh score class a or b7 based on low albumin (albumin 25-27 g/l) only

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify